Enjoy complimentary customisation on priority with our Enterprise License!
The microarray biochips market share is expected to rise to USD 14.75 billion by 2026 at a progressing CAGR of 19.95%. Furthermore, this report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches.
The microarray biochips market report offers information on several market vendors, including Abbott Laboratories, Agilent Technologies Inc., Applied Microarrays Inc., Bio Rad Laboratories Inc., BioChain Institute Inc., BioIVT LLC, Biometrix Technology Inc., Danaher Corp., F. Hoffmann La Roche Ltd., Fluidigm Corp., General Electric Co., HORIBA Ltd., Illumina Inc., Merck KGaA, OriGene Technologies Inc., Pantomics Inc., PerkinElmer Inc., Protein Biotechnologies Inc., QIAGEN NV, Randox Laboratories Ltd., RayBiotech Life Inc., Thermo Fisher Scientific Inc., and bioMerieux SA among others.
This microarray biochips market research report extensively covers market segmentation by application (drug discovery and development, diagnostics and treatments, research and consumables, forensic medicines, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Download the Free Report Sample to Unlock the Microarray Biochips Market Size for the Forecast Period and Other Important Statistics
"The presence of strong distribution networks in countries such as the US and Canada and the increasing focus of pharmaceutical companies on drug discovery and development will facilitate the tissue microarray market growth in North America over the forecast period."
Based on our research output, there has been a positive impact on the market growth during and post COVID-19 era. The increase in market presence with a collaboration strategy is notably driving the microarray biochips market growth, although factors such as capital-intensive market may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the microarray biochips industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Microarray Biochips Market Driver
One of the key factors driving the global microarray biochips market growth is the increase in market presence with a collaboration strategy. Players increase their market presence by collaborating with those companies that own bio-content. Research says that companies generate around 60% better results when they work in collaboration. They collaborate with each other for R&D, financial resources, and intellectual properties. Even manufacturers and end-user companies are also making various alliances, such as an alliance between a chip manufacturer and a pharmaceutical company.
Key Microarray Biochips Market Trend
Emerging LOC technology is one of the key microarray biochips market trends that is expected to impact the industry positively in the forecast period. LOC technology is mainly used in the field of diagnostics to perform various complex tests simultaneously. Extensive research on LOCs has thrown light on more in-depth use of the technology. LOCs with small chemical sensors made of mid-infrared and far-infrared sensing systems have improved their application in monitoring activities. Other factors such as the small size, ease of handling, and result orientation and efficiency will further increase the demand for LOCs. Moreover, due to the outbreak of the COVID-19 pandemic, LOC COVID-19 diagnostic tests are being carried out as it is an inexpensive test and also provides a result in 20 minutes. Such factors will further support the market growth in the coming years.
Key Microarray Biochips Market Challenge
One of the key challenges to the global microarray biochips market growth is the capital-intensive nature of the market despite a lot of innovations. Not only manufacturers but investors or end-users in this market are also skeptical about their ROI. Moreover, accuracy can be negatively affected, owing to a low dynamic range of the existing microarrays. In addition, there are many research institutes and diagnostic centers that are unaware of the in-depth use of microarray biochips and thus, avoid making any investment. The reason behind this is the extravagant cost associated with this technology at the very first stage. Low commercial acceptability due to high costs and the lack of skilled labor will further limit the market growth in the forecast years.
This microarray biochips market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global microarray biochips market as a part of the global healthcare equipment market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the microarray biochips market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the microarray biochips market encompasses successful business strategies deployed by the key vendors. The microarray biochips market is fragmented and the vendors are deploying growth strategies such as M&A activities to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The microarray biochips market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the microarray biochips market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
39% of the market's growth will originate from North America during the forecast period. The US is the key market for microarray biochips in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).
The well-developed infrastructure for medical research and studies of genomics and proteomics and disease outbreaks will facilitate the microarray biochips market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
Point-of-contact (POC) instruments, which are based on microfluidic technology, have played important roles in diagnosing the COVID-19 during the ongoing pandemic. For instance, in March 2020, the ID NOW instrument, introduced by Abbott in the US, detected positive samples within five minutes and negative results within 13 minutes. ID NOW, therefore, received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). Furthermore, In March 2020, BioMerieux received the Emergency Use Authorization from the US FDA for its BioFire COVID-19 test, which can be used in Clinical Laboratory Improvement Amendments (CLIA)-approved moderate and high-complexity clinical laboratories for detecting SARS-CoV-2. Therefore, microarray biochips have played a crucial role during the ongoing COVID-19 pandemic. Considering all these factors, the market in focus is expected to grow in the region during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The microarray biochips market share growth by the drug discovery and development segment will be significant during the forecast period. The advancement and the growing use of microarray biochips in the field of genomics and proteomics will result in an overall increase in market demand globally in the forecast years. This segment is also growing owing to the rising preference for personalized medicines.
This report provides an accurate prediction of the contribution of all the segments to the growth of the microarray biochips market size and actionable market insights on post COVID-19 impact on each segment.
Microarray market - The market share has the potential to grow by USD 1.21 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 5.61%.
Protein Microarray market - The market share is expected to increase by USD 1.48 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.92%.
DNA Microarray market - The market share has the potential to grow by USD 543.81 million during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 5.06%.
Microarray Biochips Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 19.95% |
Market growth 2022-2026 |
$ 14.75 billion |
Market structure |
Fragmented |
YoY growth (%) |
19.35 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key consumer countries |
US, UK, Germany, China, and Japan |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Abbott Laboratories, Agilent Technologies Inc., Applied Microarrays Inc., Bio Rad Laboratories Inc., BioChain Institute Inc., BioIVT LLC, Biometrix Technology Inc., Danaher Corp., F. Hoffmann La Roche Ltd., Fluidigm Corp., General Electric Co., HORIBA Ltd., Illumina Inc., Merck KGaA, OriGene Technologies Inc., Pantomics Inc., PerkinElmer Inc., Protein Biotechnologies Inc., QIAGEN NV, Randox Laboratories Ltd., RayBiotech Life Inc., Thermo Fisher Scientific Inc., and bioMerieux SA |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.